(0.22%) 5 110.95 points
(0.34%) 38 372 points
(0.27%) 15 970 points
(-1.36%) $82.71
(5.77%) $2.03
(0.20%) $2 351.80
(0.01%) $27.54
(3.95%) $958.50
(-0.24%) $0.932
(-0.36%) $10.99
(-0.55%) $0.796
(1.65%) $93.39
-0.20% INR 697.20
Live Chart Being Loaded With Signals
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally...
Stats | |
---|---|
Dagens volum | 957 132 |
Gjennomsnittsvolum | 906 425 |
Markedsverdi | 279.00B |
EPS | INR0 ( 2024-04-25 ) |
Neste inntjeningsdato | ( INR1.270 ) 2024-07-24 |
Last Dividend | INR0.750 ( 2023-06-30 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 54.85 |
ATR14 | INR0.405 (0.06%) |
Volum Korrelasjon
Syngene International Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Syngene International Korrelasjon - Valuta/Råvare
Syngene International Økonomi
Annual | 2023 |
Omsetning: | INR34.89B |
Bruttogevinst: | INR12.44B (35.65 %) |
EPS: | INR12.71 |
FY | 2023 |
Omsetning: | INR34.89B |
Bruttogevinst: | INR12.44B (35.65 %) |
EPS: | INR12.71 |
FY | 2022 |
Omsetning: | INR31.93B |
Bruttogevinst: | INR23.33B (73.06 %) |
EPS: | INR11.59 |
FY | 2022 |
Omsetning: | INR25.07B |
Bruttogevinst: | INR17.58B (70.12 %) |
EPS: | INR9.94 |
Financial Reports:
No articles found.
Syngene International Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0.750 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.500 | 2016-03-17 |
Last Dividend | INR0.750 | 2023-06-30 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | INR3.25 | -- |
Avg. Dividend % Per Year | 0.05% | -- |
Score | 2.87 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.39 | |
Div. Directional Score | 8.64 | -- |
Year | Amount | Yield |
---|---|---|
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.500 | 0.16% |
2019 | INR0.500 | 0.18% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0.500 | 0.08% |
2023 | INR0.750 | 0.13% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TINPLATE.NS | Dividend Junior | 2023-08-11 | Annually | 19 | 0.72% | |
PDMJEPAPER.NS | Dividend Junior | 2023-08-03 | Annually | 9 | 0.65% | |
J&KBANK.NS | Dividend Junior | 2023-08-17 | Sporadic | 22 | 0.47% | |
DATAMATICS.NS | Dividend Junior | 2023-09-22 | Annually | 21 | 0.49% | |
SHYAMMETL.NS | Dividend Junior | 2023-06-05 | Semi-Annually | 4 | 0.70% | |
MAXHEALTH.NS | Dividend Junior | 2023-09-08 | Insufficient data to determine frequency | 2 | 0.07% | |
GSPL.NS | Dividend Junior | 2023-09-01 | Annually | 19 | 0.81% | |
BANKINDIA.NS | Dividend Junior | 2023-06-20 | Sporadic | 23 | 1.34% | |
PRAJIND.NS | Dividend Junior | 2023-07-19 | Annually | 22 | 0.83% | |
KABRAEXTRU.NS | Dividend Junior | 2023-07-13 | Annually | 23 | 0.83% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.146 | 1.500 | 7.08 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0829 | 1.200 | 7.24 | 8.68 | [0 - 0.3] |
returnOnEquityTTM | 0.127 | 1.500 | 9.70 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.712 | 0.800 | 6.44 | 5.15 | [1 - 3] |
quickRatioTTM | 1.327 | 0.800 | 6.90 | 5.52 | [0.8 - 2.5] |
cashRatioTTM | 0.492 | 1.500 | 8.38 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0309 | -1.500 | 9.48 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 14.26 | 1.000 | 5.83 | 5.83 | [3 - 30] |
operatingCashFlowPerShareTTM | 20.51 | 2.00 | 3.16 | 6.33 | [0 - 30] |
freeCashFlowPerShareTTM | 20.51 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0446 | -1.500 | 9.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.636 | 1.000 | 2.73 | 2.73 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.193 | 1.000 | 8.14 | 8.14 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.32 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.567 | 0.800 | 9.55 | 7.64 | [0.5 - 2] |
Total Score | 11.90 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 54.57 | 1.000 | 4.59 | 0 | [1 - 100] |
returnOnEquityTTM | 0.127 | 2.50 | 9.80 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 20.51 | 2.00 | 3.16 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.108 | 1.500 | 7.30 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 20.51 | 2.00 | 3.16 | 6.33 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 6.60 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.235 | 1.000 | 6.62 | 0 | [0.1 - 0.5] |
Total Score | 5.39 |
Syngene International
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company provides discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also offers exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. Further, it offers other drug modalities, which include peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.